<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2664-3243</journal-id>
<journal-title><![CDATA[Vive Revista de Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Vive Rev. Salud]]></abbrev-journal-title>
<issn>2664-3243</issn>
<publisher>
<publisher-name><![CDATA[CET-BOLIVIA]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2664-32432023000100264</article-id>
<article-id pub-id-type="doi">10.33996/revistavive.v6i16.224</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Recomendaciones y peligros del uso de las benzodiacepinas en los adultos mayores]]></article-title>
<article-title xml:lang="en"><![CDATA[Recommendations and dangers of the use of benzodiazepines in older adults]]></article-title>
<article-title xml:lang="pt"><![CDATA[Recomendações e perigos da utilização de benzodiazepinas em adultos idosos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tinizaray]]></surname>
<given-names><![CDATA[Nicole Mishelle Ruiz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calle]]></surname>
<given-names><![CDATA[Diego Fernando Chalco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Católica de Cuenca  ]]></institution>
<addr-line><![CDATA[Cuenca ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<volume>6</volume>
<numero>16</numero>
<fpage>264</fpage>
<lpage>274</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S2664-32432023000100264&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S2664-32432023000100264&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S2664-32432023000100264&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Las benzodiazepinas han sido empleadas en la práctica clínica aproximadamente desde la década de los 50, sus principales recomendaciones con importante eficacia son producción de ansiólisis, hipnosis, relajación muscular o como terapia anticonvulsivante, sin embargo, pueden asociarse con algunos riesgos altamente potenciales que pueden influir directamente de forma perjudicial en la calidad de vida de los pacientes geriátricos. Objetivo. Describir las recomendaciones y peligros del uso de benzodiacepinas en los adultos mayores. Metodología. Se realizó una revisión sistemática mediante una búsqueda electrónica en las siguientes bases de datos: &#8220;PubMed&#8221; y &#8220;ScienceDirect&#8221;, fueron incluidos artículos originales, metaanálisis, ensayos clínicos, entre otros, en idioma inglés y español. Para la recolección de información se tomó en cuenta la temporalidad de los últimos 6 años. Se utilizó palabras clave como: &#8220;Aged&#8221;, &#8220;Anciano&#8221;, &#8220;Benzodiacepinas&#8221;, &#8220;Benzodiazepines&#8221; &#8220;eHealth Strategies&#8221;, &#8220;Safety Management&#8221;. Según los términos DeCS/MESH. Conclusión. Se identificaron varios usos principales para los benzodiacepinas, los cuales incluyen el tratamiento del insomnio, la depresión, el trastorno de pánico, la ansiedad y la abstinencia por alcoholismo, con una tasa de prevalencia que alcanzó el 83,5%. Se encontró que el uso de benzodiacepinas es más común en pacientes críticos o en aquellos que presentan otras comorbilidades, como demencia (33,5%) o enfermedad de Alzheimer (5%). Entre los principales factores de riesgo relacionados al uso de benzodiacepinas se encuentran las caídas, las cuales presentaron una incidencia que osciló entre el 13% y el 17,5%. Asimismo, se identificó la dependencia y la incontinencia urinaria, ambas con una tasa de prevalencia del 15%.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Benzodiazepines have been used in clinical practice since approximately the 1950s, their main recommendations with important efficacy are to produce anxiolysis, hypnosis, muscle relaxation or as anticonvulsant therapy, however, they can be associated with some highly potential risks that can directly influence in a detrimental way the quality of life of geriatric patients. Objective. To describe the recommendations and hazards of benzodiazepine use in older adults. Methodology. A systematic review was carried out by means of an electronic search in the following databases: "PubMed" and "ScienceDirect", including original articles, meta-analysis, clinical trials, among others, in English and Spanish. For the collection of information, we took into account the temporality of the last 6 years. Keywords such as: "Aged", "Elderly", "Benzodiazepines", "Benzodiazepines", "eHealth Strategies", "Safety Management" were used. According to DeCS/MESH terms. Conclusion. Several main uses for benzodiazepines were identified, which include treatment of insomnia, depression, panic disorder, anxiety, and alcohol withdrawal, with a prevalence rate reaching 83.5%. Benzodiazepine use was found to be more common in critically ill patients or in those with other comorbidities, such as dementia (33.5%) or Alzheimer's disease (5%). Among the main risk factors related to benzodiazepine use were falls, which had an incidence ranging from 13% to 17.5%. Likewise, dependence and urinary incontinence were identified, both with a prevalence rate of 15%.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO Os benzodiazepínicos têm sido usados na prática clínica desde aproximadamente a década de 1950, suas principais recomendações com eficácia significativa são para produzir ansiólise, hipnose, relaxamento muscular ou como terapia anticonvulsivante, no entanto, podem estar associados a alguns riscos de alto potencial que podem influenciar diretamente a qualidade de vida de pacientes geriátricos de forma prejudicial. Objetivo. Descrever as recomendações e os riscos do uso de benzodiazepínicos em idosos. Metodologia. Foi realizada uma revisão sistemática por meio de busca eletrônica nas seguintes bases de dados: "PubMed" e "ScienceDirect", incluindo artigos originais, meta-análises, ensaios clínicos, entre outros, em inglês e espanhol. Para a coleta de informações, foi levado em conta o período dos últimos 6 anos. As palavras-chave utilizadas foram: "Aged", "Elderly", "Benzodiazepines", "Benzodiazepines", "eHealth Strategies", "Safety Management". De acordo com os termos do DeCS/MESH. Conclusão. Foram identificados vários usos principais para os benzodiazepínicos, incluindo o tratamento de insônia, depressão, transtorno do pânico, ansiedade e abstinência de álcool, com uma taxa de prevalência de 83,5%. Verificou-se que o uso de benzodiazepínicos é mais comum em pacientes graves ou com outras comorbidades, como demência (33,5%) ou doença de Alzheimer (5%). Entre os principais fatores de risco relacionados ao uso de benzodiazepínicos estavam as quedas, cuja incidência variou de 13% a 17,5%. A dependência e a incontinência urinária também foram identificadas, ambas com uma taxa de prevalência de 15%.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Anciano]]></kwd>
<kwd lng="es"><![CDATA[Benzodiazepinas]]></kwd>
<kwd lng="es"><![CDATA[Estrategias de Salud]]></kwd>
<kwd lng="en"><![CDATA[Aged]]></kwd>
<kwd lng="en"><![CDATA[Benzodiazepines]]></kwd>
<kwd lng="en"><![CDATA[Health Strategies]]></kwd>
<kwd lng="pt"><![CDATA[Idoso]]></kwd>
<kwd lng="pt"><![CDATA[Benzodiazepinas]]></kwd>
<kwd lng="pt"><![CDATA[Estratégias de Saúde]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rausch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[van Zon]]></surname>
<given-names><![CDATA[SKR]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Laflamme]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Möller]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de Rooij]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Geriatric Syndromes and Incident Chronic Health Conditions Among 9094 Older Community-Dwellers: Findings from the Lifelines Cohort Study.]]></article-title>
<source><![CDATA[Journal of the American Medical Directors Association.]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velert Vila]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Velert Vila]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Salar Ibáñez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Avellana Zaragoza]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno Royo]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adecuación de la utilización de benzodiazepinas en ancianos desde la oficina de farmacia. Un estudio de colaboración médico-farmacéutico.]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2012</year>
<volume>44</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>402-10</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<collab>By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel</collab>
<article-title xml:lang=""><![CDATA[American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults]]></article-title>
<source><![CDATA[Journal of the American Geriatrics Society]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Landon]]></surname>
<given-names><![CDATA[BE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patterns in Outpatient Benzodiazepine Prescribing in the United States]]></article-title>
<source><![CDATA[Internet ;. JAMA Network Open]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Picton]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Marino]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Nealy]]></surname>
<given-names><![CDATA[KL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benzodiazepine use and cognitive decline in the elderly]]></article-title>
<source><![CDATA[American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Merrill]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives]]></article-title>
<source><![CDATA[Journal of Clinical Medicine. Multidisciplinary Digital Publishing Institute]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sateia]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Buysse]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Krystal]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Neubauer]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Heald]]></surname>
<given-names><![CDATA[JL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline]]></article-title>
<source><![CDATA[Journal of Clinical Sleep Medicine. American Academy of Sleep Medicine]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jobert]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Laforgue]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Grall-Bronnec]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rousselet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Péré]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jolliet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients?]]></article-title>
<source><![CDATA[European Journal of Clinical Pharmacology]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kurko]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Saastamoinen]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Tuulio-Henriksson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Taiminen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tiihonen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Airaksinen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in the long-term use of benzodiazepine anxiolytics and hypnotics: A national register study for 2006 to 2014]]></article-title>
<source><![CDATA[Pharmacoepidemiology and Drug Safety]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carlisle]]></surname>
<given-names><![CDATA[JB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Data fabrication and other reasons for non-random sampling in 5087 randomised, controlled trials in anaesthetic and general medical journals]]></article-title>
<source><![CDATA[Anaesthesia]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brooks]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries]]></article-title>
<source><![CDATA[JAMA Network Open]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hessmann]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zeidler null]]></surname>
<given-names><![CDATA[Jan]]></given-names>
</name>
<name>
<surname><![CDATA[Neubauer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abdel-Hamid]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Stahmeyer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Eberhard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Continuity of treatment with benzodiazepines in dementia patients: an analysis of German health insurance claims data]]></article-title>
<source><![CDATA[International Clinical Psychopharmacology]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tracy]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Gan]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease]]></article-title>
<source><![CDATA[Current Opinion in Neurobiology]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rae]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Montagu]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term benzodiazepine and Z-drugs use in England: a survey of general practice]]></article-title>
<source><![CDATA[British Journal of General Practice. British Journal of General Practice]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerlach]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Wiechers]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Maust]]></surname>
<given-names><![CDATA[DT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prescription benzodiazepine use among older adults: A critical review]]></article-title>
<source><![CDATA[Harvard review of psychiatry]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez-Cengotitabengoa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz-Gutierrez]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Besga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bermúdez-Ampudia]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rondon]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benzodiazepine prescriptions and falls in older men and women]]></article-title>
<source><![CDATA[Revista de Psiquiatría y Salud Mental (English Edition)]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gress]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meadows]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Neitch]]></surname>
<given-names><![CDATA[SM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benzodiazepine Overuse in Elders: Defining the Problem and Potential Solutions]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vordenberg]]></surname>
<given-names><![CDATA[SE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Older adults&#8217; perceptions of deprescribing chronic benzodiazepines]]></article-title>
<source><![CDATA[Journal of the American Pharmacists Association: JAPhA]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baandrup]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ebdrup]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[JØ]]></given-names>
</name>
<name>
<surname><![CDATA[Lindschou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gluud]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Glenthøj]]></surname>
<given-names><![CDATA[BY.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users]]></article-title>
<source><![CDATA[The Cochrane Database of Systematic Reviews]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aljawadi]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Khoja]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Alhammad]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[AlOtaibi]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Shammari]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Khoja]]></surname>
<given-names><![CDATA[TA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prevalence of benzodiazepines utilization and its association with falls among Saudi older adults; results from the Saudi national survey for elderly Health (SNSEH)]]></article-title>
<source><![CDATA[Saudi pharmaceutical journal: SPJ: the official publication of the Saudi Pharmaceutical Society]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nafti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sirois]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kröger]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Carmichael]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Laurin]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is Benzodiazepine Use Associated with the Risk of Dementia and Cognitive Impairment-Not Dementia in Older Persons? The Canadian Study of Health and Aging]]></article-title>
<source><![CDATA[The Annals of Pharmacotherapy]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivasi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kenny]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Ungar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Romero-Ortuno]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of benzodiazepines on orthostatic blood pressure in older people]]></article-title>
<source><![CDATA[European Journal of Internal Medicine]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rudoler]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[de Oliveira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kurdyak]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Iaboni]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: A population-based cohort study]]></article-title>
<source><![CDATA[Journal of Psychopharmacology (Oxford, England)]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quijano]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Ruíz]]></surname>
<given-names><![CDATA[JRT]]></given-names>
</name>
<name>
<surname><![CDATA[Aparicio]]></surname>
<given-names><![CDATA[VR]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo]]></surname>
<given-names><![CDATA[MG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consumo de benzodiacepinas en adultos mayores atendidos en el CITED. 2017]]></article-title>
<source><![CDATA[Revista del Hospital Psiquiátrico de La Habana]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an intensive care unit]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Markota]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rummans]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Bostwick]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Lapid]]></surname>
<given-names><![CDATA[MI.]]></given-names>
</name>
</person-group>
<source><![CDATA[Benzodiazepine Use in Older Adults: Dangers, Management, and Alternative Therapies. Mayo Clinic Proceedings]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amari]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Juday]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Frech]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Atkins]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepines]]></article-title>
<source><![CDATA[BMC Geriatrics]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Celikkayalar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Airaksinen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kivelä]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Nieminen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kleme]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Puustinen]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are Older People Aware of Potential Risks Related to Benzodiazepines They are Taking and Has Anything Changed in Risk Awareness Over Ten Years?]]></article-title>
<source><![CDATA[Patient preference and adherence.]]></source>
<year>2021</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
